Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.

Larkin EL, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, Wring S, Ghannoum M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02611-18. doi: 10.1128/AAC.02611-18. Print 2019 May.

PMID:
30885896
2.

SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats.

Wring S, Borroto-Esoda K, Solon E, Angulo D.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e02119-18. doi: 10.1128/AAC.02119-18. Print 2019 Feb.

3.

Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis.

Ghannoum M, Long L, Larkin EL, Isham N, Sherif R, Borroto-Esoda K, Barat S, Angulo D.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00244-18. doi: 10.1128/AAC.00244-18. Print 2018 Jun.

4.

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.

Schell WA, Jones AM, Borroto-Esoda K, Alexander BD.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01102-17. doi: 10.1128/AAC.01102-17. Print 2017 Nov.

5.

De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.

Jiménez-Ortigosa C, Perez WB, Angulo D, Borroto-Esoda K, Perlin DS.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00833-17. doi: 10.1128/AAC.00833-17. Print 2017 Sep.

6.

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00161-17. doi: 10.1128/AAC.00161-17. Print 2017 Aug.

7.

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, Wring S, Angulo D, Ghannoum M.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02396-16. doi: 10.1128/AAC.02396-16. Print 2017 May.

8.

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02068-16. doi: 10.1128/AAC.02068-16. Print 2017 Apr.

9.

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.

Scorneaux B, Angulo D, Borroto-Esoda K, Ghannoum M, Peel M, Wring S.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01961-16. doi: 10.1128/AAC.01961-16. Print 2017 Mar.

10.

Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells.

Daito T, Watashi K, Sluder A, Ohashi H, Nakajima S, Borroto-Esoda K, Fujita T, Wakita T.

Gastroenterology. 2014 Aug;147(2):463-72. doi: 10.1053/j.gastro.2014.04.035. Epub 2014 Apr 29.

PMID:
24786893
11.

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).

Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T.

Hepatology. 2014 May;59(5):1726-37. doi: 10.1002/hep.26982. Epub 2014 Apr 1.

12.

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD.

Hepatology. 2014 Feb;59(2):434-42.

PMID:
23939953
13.

Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F.

J Hepatol. 2013 Oct;59(4):684-95. doi: 10.1016/j.jhep.2013.05.038. Epub 2013 Jun 3.

PMID:
23742912
14.

Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.

Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, Lavocat F, Zoulim F, Kitrinos KM.

J Viral Hepat. 2013 Feb;20(2):131-40. doi: 10.1111/j.1365-2893.2012.01638.x. Epub 2012 Jul 9.

PMID:
23301548
15.

Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.

Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, Reuman EC, Holmes SP, Borroto-Esoda K, Shafer RW.

Antimicrob Agents Chemother. 2013 Jan;57(1):343-9. doi: 10.1128/AAC.01601-12. Epub 2012 Oct 31.

16.

Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States.

Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC.

J Hepatol. 2013 Feb;58(2):212-6. doi: 10.1016/j.jhep.2012.09.014. Epub 2012 Sep 26.

PMID:
23022497
17.

The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.

Zhu Y, Curtis M, Borroto-Esoda K.

Antivir Chem Chemother. 2011 Aug 23;22(1):13-22. doi: 10.3851/IMP1791.

PMID:
21860069
18.

Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.

McColl DJ, Margot N, Chen SS, Harris J, Borroto-Esoda K, Miller MD.

HIV Clin Trials. 2011 Mar-Apr;12(2):61-70. doi: 10.1310/hct1202-61.

PMID:
21498149
19.

HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays.

Zhu Y, Curtis M, Borroto-Esoda K.

J Virol Methods. 2011 May;173(2):340-6. doi: 10.1016/j.jviromet.2011.03.006. Epub 2011 Mar 17.

PMID:
21396961
20.

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.

Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K.

Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22.

PMID:
21374657
21.

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.

Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, Miller MD, Svarovskaia ES.

AIDS. 2011 Jan 28;25(3):325-33. doi: 10.1097/QAD.0b013e3283427dcb.

PMID:
21157296
22.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F.

Gastroenterology. 2011 Jan;140(1):132-43. doi: 10.1053/j.gastro.2010.10.011. Epub 2010 Oct 16.

PMID:
20955704
23.

A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads.

Reuman EC, Margeridon-Thermet S, Caudill HB, Liu T, Borroto-Esoda K, Svarovskaia ES, Holmes SP, Shafer RW.

Bioinformatics. 2010 Dec 1;26(23):2929-32. doi: 10.1093/bioinformatics/btq570. Epub 2010 Oct 11.

24.

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F.

Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20.

PMID:
20600025
25.

Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives.

Koch K, Chen Y, Feng JY, Borroto-Esoda K, Deville-Bonne D, Gallois-Montbrun S, Janin J, Moréra S.

Nucleosides Nucleotides Nucleic Acids. 2009 Aug;28(8):776-92. doi: 10.1080/15257770903155899. Erratum in: Nucleosides Nucleotides Nucleic Acids. 2009 Oct;28(10):987. Gallois-Montbrun, Sarah [added].

PMID:
20183617
26.

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto-Esoda K, Miller MD.

Retrovirology. 2009 May 13;6:44. doi: 10.1186/1742-4690-6-44.

27.

Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.

Waters JM, O'Neal W, White KL, Wakeford C, Lansdon EB, Harris J, Svarovskaia ES, Miller MD, Borroto-Esoda K.

Antivir Ther. 2009;14(2):231-9.

PMID:
19430098
28.

Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.

Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K.

Antivir Chem Chemother. 2009;19(4):165-76.

PMID:
19374144
29.

Therapy of chronic hepatitis B: trends and developments.

Delaney WE 4th, Borroto-Esoda K.

Curr Opin Pharmacol. 2008 Oct;8(5):532-40. doi: 10.1016/j.coph.2008.09.008. Epub 2008 Oct 6. Review.

PMID:
18835366
30.

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F.

Hepatology. 2008 Sep;48(3):750-8. doi: 10.1002/hep.22414.

PMID:
18752330
31.

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.

PMID:
18614922
32.

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.

Borroto-Esoda K, Parkin N, Miller MD.

Antivir Chem Chemother. 2007;18(5):297-300.

PMID:
18046962
33.

Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.

Curtis M, Zhu Y, Borroto-Esoda K.

J Infect Dis. 2007 Nov 15;196(10):1483-6. Epub 2007 Oct 31.

PMID:
18008227
34.

Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.

Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, Quinn JB, Rousseau FS.

AIDS Res Hum Retroviruses. 2007 Aug;23(8):988-95.

PMID:
17725415
35.

Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.

Borroto-Esoda K, Miller MD, Arterburn S.

J Hepatol. 2007 Oct;47(4):492-8. Epub 2007 Jul 23.

PMID:
17692425
36.

In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations.

Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, Borroto-Esoda K.

J Clin Microbiol. 2007 Oct;45(10):3335-41. Epub 2007 Aug 8.

37.

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):174-80.

PMID:
17667333
38.

Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S; Adefovir Dipivoxil Study 45 Intrnational Investigators Group.

Liver Transpl. 2007 Mar;13(3):349-60.

39.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group.

Gastroenterology. 2006 Dec;131(6):1743-51. Epub 2006 Sep 20.

PMID:
17087951
40.

MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.

Svarovskaia ES, Moser MJ, Bae AS, Prudent JR, Miller MD, Borroto-Esoda K.

J Clin Microbiol. 2006 Nov;44(11):4237-41. Epub 2006 Sep 27.

41.

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD.

Antivir Ther. 2006;11(3):377-84.

PMID:
16759055
42.

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B.

Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107.

PMID:
16440988
43.

Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.

Feng JY, Myrick F, Selmi B, Deval J, Canard B, Borroto-Esoda K.

Antiviral Res. 2005 Jun;66(2-3):153-8. Epub 2005 Apr 26.

PMID:
15885814
45.

Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases.

Feng JY, Parker WB, Krajewski ML, Deville-Bonne D, Veron M, Krishnan P, Cheng YC, Borroto-Esoda K.

Biochem Pharmacol. 2004 Nov 1;68(9):1879-88.

PMID:
15450953
46.

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team.

JAMA. 2004 Jul 14;292(2):180-9.

PMID:
15249567
47.

Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach.

Chong Y, Borroto-Esoda K, Furman PA, Schinazi RF, Chu CK.

Antivir Chem Chemother. 2002 Mar;13(2):115-28.

PMID:
12238529
48.

Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.

Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B, Borroto-Esoda K.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):11-20.

PMID:
11782585
49.

Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.

Furman PA, Jeffrey J, Kiefer LL, Feng JY, Anderson KS, Borroto-Esoda K, Hill E, Copeland WC, Chu CK, Sommadossi JP, Liberman I, Schinazi RF, Painter GR.

Antimicrob Agents Chemother. 2001 Jan;45(1):158-65.

50.

Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.

Szczech GM, Furman P, Painter GR, Barry DW, Borroto-Esoda K, Grizzle TB, Blum MR, Sommadossi J, Endoh R, Niwa T, Yamamoto M, Moxham C.

Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.

Supplemental Content

Loading ...
Support Center